Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REP. DINGELL PUTTING INDIRECT PRESSURE ON BOLAR TO COME CLEAN

Executive Summary

REP. DINGELL PUTTING INDIRECT PRESSURE ON BOLAR TO COME CLEAN "concerning false documents" submitted to the House Energy & Commerce/Oversight Subcommittee in its investigation of FDA's generic approval process. In a March 19 letter to Lt. General Charles McCausland, USAF, who is considering debarring Bolar from Defense Department contracts, Rep. John Dingell (D-Mich.) expressed the subcommittee's "continuing concern about the lack of full cooperation...by Bolar's new management, as well as about Bolar's now legendary misdeeds." Dingell noted that the subcommittee had asked Bolar, in a Jan. 23 letter to the company's legal counsel, to make "a full and public accounting concerning the false documents submitted to the subcommittee." At that time, the subcommittee also asked the company to release the results of its own internal investigations. "None of this information has been provided," Dingell pointed out. "Even had there been belated cooperation, Bolar's misbehavior has been so extensive that it would support significant enforcement action." In addition, the Michigan congressman characterized Bolar's "unwillingness to cooperate with federal authorities...and to disclose the full nature and extent of its efforts to subvert" the investigation as "particularly grave matters." Bolar said that although it has not yet responded to Dingell's request for information, the company is cooperating with the Justice Department's investigation of the the firm.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel